Tepezza

eye eyeball eye art
Biotech

Sling's oral Tepezza rival hits goal in thyroid eye disease

A cross-trial comparison suggests Amgen’s blockbuster may have the advantage on the efficacy front.
Nick Paul Taylor Jan 14, 2025 8:16am
eye eyeball eye art

Viridian eye disease phase 3 hits, advancing push to rival Amgen

Sep 10, 2024 8:10am
Businessman puts his box of his belongs on the desk and holds a white letter

Acelyrin loses interest in izokibep, lays off 3rd of staff

Aug 13, 2024 4:00pm
Two hands gripping onto a rope seemingly tugging in opposite directions

Acelyrin's proof-of-concept TED data cement Amgen challenge

Mar 20, 2024 7:00am